Who Paid My Doc Search
Menu
Product Program year 2020 Source: CMS Open Payments

Cabozantinib

Drug Oncology

NDC 42388-023-26

Open in the dashboard

General payments

$1,716,998

159 payments

Research payments

$30,190,707

3,271 payments

Through program year 2020, $1,716,998 in general payments and $30,190,707 in research payments were reported against Cabozantinib (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $848,135 73
2020 Research $19,418,643 2,378
2019 General $868,864 86
2019 Research $10,772,063 893

Breakdown

Who paid General payments · program years 2019–2020
  1. Exelixis Inc. $1,716,998 159 payments
Top recipients General payments · program year 2020
  1. Denver Health Medical Center Teaching hospital · CO $585,292 69% · 23 payments
  2. Stephen Sherwin Medical Oncology · San Francisco, CA $120,000 14% · 4 payments
  3. Lori Cirangle Madison, NJ $43,990 5% · 11 payments
  4. Ut Md Anderson Cancer Center Teaching hospital · TX $37,600 4% · 1 payment
  5. Ronald Bukowski Hematology & Oncology · Cleveland, OH $32,780 4% · 7 payments

The top 5 of 24 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Medical Oncology Internal Medicine $132,801 77% · 7 practitioners
  2. Hematology & Oncology Internal Medicine $35,514 21% · 7 practitioners
  3. Endocrinology, Diabetes & Metabolism Internal Medicine $3,192 2% · 2 practitioners
  4. Internal Medicine $704 <1% · 2 practitioners
  5. Pediatric Hematology-Oncology Pediatrics $42 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. Colorado $585,292 69% · 1 recipient
  2. California $120,771 14% · 4 recipients
  3. New Jersey $43,990 5% · 1 recipient
  4. Texas $37,751 4% · 4 recipients
  5. Ohio $35,930 4% · 2 recipients

The top 5 of 15 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Records

159 general · 3,271 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record